Skip to the page

Data / Drug companies / Piramal Critical Care Inc

Piramal Critical Care Inc: 41 products in the FDA NDC directory, labeler code 66794

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Piramal Critical Care Inc (labeler code 66794) lists 41 products in the FDA National Drug Code Directory, covering 18 finished drugs by generic name. By type: 39 prescription drugs, 2 bulk ingredients. Its main marketing category is generic drugs (ANDA). The newest product started marketing on October 25, 2026.

The request: Watch Piramal Critical Care Inc (FDA labeler code 66794): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
66794
Products in commercial distribution
41
Packages
48
Finished drugs by generic name
18
Prescription products
39
Over the counter products
0
Controlled substance products
Schedule II 2
Flagged as original packager
38 of 38 products that carry the flag
Started marketing in the last 12 months
3
Earliest marketing start
February 28, 2010
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Generic drugs (ANDA)3482.9%
New drug applications (NDA)49.8%
Bulk ingredients24.9%
Other unapproved drugs12.4%

Products by type

TypeProductsShare
Prescription drugs3995.1%
Bulk ingredients24.9%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

Dosage forms

Dosage formProductsShare
Injection, solution1843.9%
Liquid1126.8%
Injection922%
Injection, powder, for solution24.9%
Injection, powder, lyophilized, for solution12.4%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Desflurane66794-021LiquidGeneric drugs (ANDA)October 25, 2026
Erythromycin Lactobionate66794-251Injection, powder, for solutionGeneric drugs (ANDA)August 13, 2026
Desflurane66794-021LiquidOther unapproved drugsJuly 1, 2026
Sevoflurane66794-023LiquidBulk ingredientsSeptember 22, 2025
Chlorpromazine hydrochloride66794-250InjectionGeneric drugs (ANDA)December 1, 2024
Chlorpromazine hydrochloride66794-249InjectionGeneric drugs (ANDA)December 1, 2024
Edaravone66794-259Injection, solutionGeneric drugs (ANDA)July 8, 2024
Linezolid66794-236InjectionGeneric drugs (ANDA)March 8, 2024
Linezolid66794-219Injection, solutionGeneric drugs (ANDA)March 8, 2024
Zinc Sulfate66794-255Injection, solutionGeneric drugs (ANDA)November 30, 2023
Pantoprazole sodium i.v.66794-258Injection, powder, for solutionGeneric drugs (ANDA)October 10, 2023
Doxycycline66794-237Injection, powder, lyophilized, for solutionGeneric drugs (ANDA)June 5, 2023
Levothyroxine Sodium66794-201InjectionGeneric drugs (ANDA)October 1, 2022
Levothyroxine Sodium66794-200InjectionGeneric drugs (ANDA)October 1, 2022
Zinc Sulfate66794-240Injection, solutionGeneric drugs (ANDA)June 20, 2022
Zinc Sulfate66794-239Injection, solutionGeneric drugs (ANDA)June 20, 2022
Dexmedetomidine66794-233Injection, solutionGeneric drugs (ANDA)May 1, 2021
Dexmedetomidine Hydrochloride66794-235InjectionGeneric drugs (ANDA)April 1, 2021
Dexmedetomidine Hydrochloride66794-234InjectionGeneric drugs (ANDA)April 1, 2021
Succinylcholine Chloride66794-232Injection, solutionGeneric drugs (ANDA)January 20, 2021
Dexmedetomidine66794-230Injection, solutionGeneric drugs (ANDA)January 19, 2021
Sevoflurane66794-022LiquidGeneric drugs (ANDA)October 1, 2020
Rocuronium66794-229Injection, solutionGeneric drugs (ANDA)July 20, 2020
Rocuronium66794-228Injection, solutionGeneric drugs (ANDA)July 20, 2020
Glycopyrrolate66794-205Injection, solutionGeneric drugs (ANDA)July 11, 2019

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.